Danaher

DHR tumbled over 11% yesterday after Q2's mixed message—EPS beat (+59.74% YoY) offset by weak 2026 revenue guidance and bioprocess order delays, the stock's worst day in over two decades. Today's session swung wildly from a $180.12 high to a $173 low, closing near flat at $179.14, then slipping to $178.61 post-market. The underlying issue: just 5.54% YoY revenue growth amid bioprocess weakness points to continued 2026 headwinds. Stock now trades 26% below its $242.8 52-week high and down 22% year-to-date. Cepheid's new third-generation GeneXpert and sustained $230 analyst price targets suggest recovery hopes, though order stabilization remains the key near-term inflection point.

DHR.US declined sharply by approximately 11% today, with the stock dropping from the previous close of $201.11 to a low of $166.67. Pre-market trading (starting at 04:00 ET) saw accelerated selling to $169.49; although the stock touched a high of $203.48 during this period, it quickly reversed lower. Regular trading hours saw a partial rebound to $179.01 (close at 15:59 ET), though insufficient to recover the intraday losses, followed by continued weakness in post-market trading. Financial data suggests underlying headwinds: Q1 revenue of $5.951B declined roughly 13% sequentially, with net profit down 14% quarter-over-quarter, though year-over-year growth at 7.86% indicates deceleration that may prompt growth expectation resets. Valuation-wise, the PE ratio of 34.34 remains elevated and vulnerable to compression as growth outlooks adjust. From a price perspective, the stock has retreated 22.3% year-to-date, currently trading 26% below its 52-week high of $242.8 and trading below both its 20-day ($194.74) and 60-day ($182.23) moving averages, reflecting sustained downward pressure.

Danaher declined 1.34% to $201.11 today, primarily due to profit-taking pressure following the intraday early surge; the stock reached an intraday high of $205.33 in pre-market trading at 21:13 Beijing time, but subsequently gapped lower to $201.43 at market open, ultimately closing at $201.11 with further weakness to $200.68 in post-market session. Q1 revenue of $5.951 billion showed 3.66% year-over-year growth and net income of $1.029 billion rose 7.86% YoY, with stable but non-accelerating momentum; the current PE ratio of 38.58x reflects elevated valuation pressure. The stock has declined 12.71% year-to-date and trades 17.17% below the 52-week high of $242.80 set on January 22, but remains supported above its 20-day moving average of $194.70 and 60-day moving average of $182.22, with solid technical support intact.

DHR pulled back 1.5% today, declining from yesterday's close of $205.01 to $203.83, with the post-market session breaking below $202, primarily driven by capital rotation ahead of Q3 earnings. Pre-market trading showed a brief rebound to $205.51, but the stock retreated from an intraday high of $206.41, with post-market losses expanding to 1.46%. Despite Q1 earnings showing revenue of $5.951 billion (+3.66% YoY) and EPS of $1.45 (+9.85% YoY), alongside positive indicators from the Masimo acquisition and bioprocessing business rebound, the stock's 39.11x PE valuation remains elevated. YTD performance is down 11.53%, with the stock trading 16.05% below its 52-week high of $242.8, reflecting profit-taking pressure as investors shift strategy ahead of earnings announcements and broader market rotation into cyclicals.

Danaher rose 2.1% to $205.01 today, driven primarily by optimism surrounding the Masimo acquisition upside and a rebound in the bioprocessing segment, with intraday gains reaching $205.24 at 10:58 AM ET. Q1 results showed revenue of $5.951 billion (+3.66% YoY) and EPS of $1.45 (+9.85% YoY), demonstrating solid earnings momentum. Valuation-wise, DHR is trading 6.7% above its 20-day moving average and 12.7% above the 60-day MA, having climbed 27.4% from the 52-week low of $160.93 but remaining about 15.6% below the January 22 peak of $242.8; year-to-date performance is down 11%. Post-market trading showed continued strength at $203 with a market cap of $145.1 billion. That said, Q1 results showed sequential declines versus Q4, and the stock's elevated P/E ratio of 39.33 means future guidance will be critical to justifying current valuations.